Delivery of antiemetics through an inhalation route
First Claim
1. A method of treating emesis comprising administering a therapeutic amount of a antiemetic condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% antiemetic degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antiemetic, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antiemetic degradation products. In a kit aspect of the present invention, a kit for delivering an antiemetic through an inhalation route is provided which comprises: a) a thin layer of an antiemetic drug and b) a device for dispensing said thin layer an antiemetic as a condensation aerosol.
81 Citations
24 Claims
-
1. A method of treating emesis comprising administering a therapeutic amount of a antiemetic condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% antiemetic degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
10. A method of treating emesis comprising administering a therapeutic amount of a dolasetron, granisetron or metoclopramide condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% dolasetron, granisetron or metoclopramide degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (11, 12, 13)
-
14. A method of administering an antiemetic to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of an antiemetic having less than 5% antiemetic degradation products and an MMAD less than 3 microns wherein the peak plasma concentration of the antiemetic is achieved in less than 0.1 hours.
-
15. A method of administering dolasetron, granisetron or metoclopramide to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of dolasetron, granisetron or metoclopramide having less than 5% dolasetron, granisetron or metoclopramide degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration of dolasetron, granisetron or metoclopramide is achieved in less than 0.1 hours.
-
16. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of an antiemetic composition and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24)
-
Specification